Aquestive Therapeutics (AQST) Income from Continuing Operations (2017 - 2026)

Aquestive Therapeutics' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 8057000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 64.86% year-over-year to 8057000.0 in Q1 2026; TTM through Mar 2026 was 68911000.0, a 27.05% decrease from a year earlier, with the FY2025 full-year figure at 83784000.0, down 89.83% from the prior year.
• Income from Continuing Operations advanced to 8057000.0 in Q1 2026 per AQST's latest filing, from 31860000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 8068000.0 in Q1 2023 and bottomed at 31860000.0 in Q4 2025.
• The 5-year median for Income from Continuing Operations is 12536000.0 (2022), against an average of 11662235.29.
• Across the five-year window, Income from Continuing Operations jumped 161.03% in 2023 and plunged 465.55% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 12352000.0 in 2022, then jumped by 34.33% to 8111000.0 in 2023, then slumped by 110.27% to 17055000.0 in 2024, then sank by 86.81% to 31860000.0 in 2025, then surged by 74.71% to 8057000.0 in 2026.
• Per Business Quant, the three latest AQST Income from Continuing Operations figures stand at 8057000.0 (Q1 2026), 31860000.0 (Q4 2025), and 15446000.0 (Q3 2025).